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ABSTRACT
GC 50 splice sites (50ss) are present in  1% of human
introns, but factors promoting their efficient selec-
tion are poorly understood. Here, we describe a
case of X-linked agammaglobulinemia resulting
from a GC 50ss activated by a mutation in BTK
intron 3. This GC 50ss was intrinsically weak, yet it
was selected in >90% primary transcripts in the
presence of a strong and intact natural GT counter-
part. We show that efficient selection of this GC 50ss
required a high density of GAA/CAA-containing
splicing enhancers in the exonized segment and
was promoted by SR proteins 9G8, Tra2b and
SC35. The GC 50ss was efficiently inhibited by
splice-switching oligonucleotides targeting either
the GC 50ss itself or the enhancer. Comprehensive
analysis of natural GC-AG introns and previously
reported pathogenic GC 50ss showed that their effi-
cient activation was facilitated by higher densities of
splicing enhancers and lower densities of silencers
than their GT 50ss equivalents. Removal of the
GC-AG introns was promoted to a minor extent by
the splice-site strength of adjacent exons and in-
hibited by flanking Alu repeats, with the first down-
stream Alus located on average at a longer distance
from the GC 50ss than other transposable elements.
These results provide new insights into the splicing
code that governs selection of noncanonical splice
sites.
INTRODUCTION
Eukaryotic genes contain introns that are removed by
splicing of precursor messenger RNAs (pre-mRNAs)
to ensure accurate and efﬁcient gene expression.
This process is accomplished by the spliceosome, a large
and highly dynamic RNA–protein complex that is
assembled in a step-wise manner on each intron (1).
Intron recognition is mediated by splicing signals on the
pre-mRNA that include 50 and 30 splices sites (ss), branch
point sequence (BPS), polypyrimidine tract and auxiliary
sequences that promote (enhancers) or inhibit (silencers)
splicing and participate in ligand binding and/or structural
interactions (2–4). Unlike in lower eukaryotes, splicing
recognition sequences in vertebrates are highly degenerate,
particularly in mammals and especially in primates (2,5,6).
This highlights the importance of the auxiliary signals for
accurate intron removal and exon ligation.
The human 50ss consensus sequence (MAG/GURAGU,
M is A or C; R is G or A) spans from position  3t o
position +6 relative to the exon–intron junction (/) and
base-pairs with the U1 small nuclear RNA (snRNA) (7).
This interaction is important for the earliest step of the
spliceosome assembly, but may not be necessary in some
cases (8). For example, U1 snRNA-depleted in vitro
splicing reactions could be reconstituted with other
factors, such as serine/arginine-rich (SR) proteins (9),
which facilitate exon inclusion by participating in
cross-exon interactions and play a more general role in
coupled gene expression pathways, including transcription
and translation (10,11).
Human GC 50ss are present in  1% of authentic introns
(12–14). They accumulated extensively during mammalian
evolution (15) and are particularly frequent in alternative-
ly spliced introns ( 1 in 20 human introns) as opposed to
those spliced constitutionally ( 1 in 200) (12). GC 50 ss are
also enriched among aberrant 50 ss activated by pathogen-
ic mutations relative to their GT counterparts (16).
Alternative 50 GCs are most commonly found 4nt down-
stream or upstream from predominant 50ss (17). This has
been attributed to the U1 snRNP binding at the 50ss,
which frequently contains a GU dinucleotide 4nt down-
stream from the dominant 50ss (17). The GC 50ss are
*To whom correspondence should be addressed. Tel: +44 2380 796425; Fax: +44 2380 794264; Email: igvo@soton.ac.uk
Published online 23 May 2011 Nucleic Acids Research, 2011, Vol. 39, No. 16 7077–7091
doi:10.1093/nar/gkr306
 The Author(s) 2011. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.intrinsically weaker than their GT counterparts because
the T>C substitution at intron position +2 introduces a
mismatch in the U1 snRNA:50ss pre-mRNA helix, but the
rest of the 50ss consensus is on average stronger, both in
humans and in lower organisms, apparently compensating
for the +2T>C transition (13,14,18–22). Canonical GT
dinucleotides at the exon–intron junction can be
replaced by GC without loss of cleavage accuracy, but
splicing of 50GC mutants is considerably slower (23).
Although both GC-AG and GT-AG introns are
recognized by the major U2 spliceosome (23), auxiliary
factors that facilitate accurate selection of weak GC 50ss
as opposed to strong GT 50ss are poorly understood.
In this work, we report an efﬁcient activation of weak
GC 50ss that was induced by a point mutation causing
X-linked agammaglobulinemia (XLA), the ﬁrst described
immunodeﬁciency (24). We identify both cis- and trans-
acting factors promoting or repressing the use of this
aberrant splice site. Compilation of GC-AG introns and
pathogenic 50GC splice sites allowed us to systematically
characterize auxiliary splicing motifs and elements that
contribute to accurate selection of such weak
pre-mRNA signals.
MATERIAL AND METHODS
BTK mutation screening
Whole blood samples of clinically diagnosed XLA
patients were collected in Paxgene
TM
Blood RNA tubes
(PreAnalytiX GmbH), which permits their storage at
room temperature for up to 72h without any degradation
of RNA. RNA was extracted by using Paxgene
TM
Blood
RNA Kit (PreAnalytiX GmbH) according to the manu-
facturer’s protocol. Synthesis of complementary DNA
(cDNA) was performed using 500ng of total RNA,
random hexamers and the First-strand cDNA synthesis
kit (Roche Applied Science) according to the manufactur-
er’s recommendations. Aberrant transcripts were
visualized using reverse transcription (RT)-polymerase
chain reaction (PCR) with primers C (50-ccg gat cca tgg
ccg cag tga ttc tgg a) and D (50-gat act gcc cat cga tcc ag).
Direct sequencing of aberrant transcripts and DNA was
carried out with the Big Dye Terminator Cycle Sequencing
kit (Applied Biosystems).
Splicing reporter constructs
The wild-type (WT) BTK reporter construct was cloned in
NheI/EcoRI sites of pCR3.1 (Invitrogen) using primers A
(BTK-NheI; 50-gat cgc tag cac aca ggt gaa ctc cag a) and B
(BTK-EcoRI; 50-gat cga att cct gga agg gat aag gga ac).
The plasmids were propagated in the Escherichia coli
strain DH5a (Invitrogen). Plasmid DNA samples were ex-
tracted as described (25). Splicing reporters with the
disease-causing T>G mutation was prepared using
overlap-extension PCR with primer M (50-tgg aac acg
ggc aag ttt cct t). Deletion mutants were prepared using
primers BTKdel-F (50-caa ttt cag tag cat agc tac cta act cct)
and BTKdel-R (50-ggt agc tat gct act gaa att gat ata tat).
Mutations introduced in putative enhancers within the
newly exonized segment are shown in Figure 1. All
constructs were fully sequenced using vector primers
PL3 and PL4 (26) and an internal primer S (50-aat gtc
tga gat ggg gaa c) to conﬁrm the intended mutations
and exclude undesired changes.
For preparation of constructs capable of splicing in
nuclear extracts, we ampliﬁed a 0.3-kb segment containing
BTK exon 3 and adjacent exonized intronic sequences with
primers BTK-PY7-F-NheI( 5 0-ata ggc tag cag aga aga ggc
agt aag aag) and BTK-PY7-R-XhoI (50-ata gct cga gat atg
aag gaa aga agc taa) and cloned into NheI/XhoI sites of
pCR3.1 (Invitrogen). The XhoI/XbaI fragment of an
in vitro splicing-proﬁcient construct PY7 (27) was cloned
downstream of BTK exon 3. Before crosslinking experi-
ments, the hybrid BTK-PY7 construct was transfected into
human embryonal kidney 293T and HeLa cells to conﬁrm
the GC 50ss activation.
Cell cultures and transfections
A pre-B cell line Nalm-6, 293T and HeLa cells were
cultured as described previously (25,28). Transient trans-
fections were carried out using Fugene HD (Roche) ac-
cording to manufacturer’s recommendations. Cells were
harvested 48h post-transfection.
For RNA interference (RNAi)-mediated depletion,
293T cells were subjected to a two-hit transfection with
custom-made small interfering RNA (siRNA) duplexes
(MWG Biotech) on Days 2 and 3, reporters were added
on Day 4 and cells were harvested 24h later, essentially as
described (6). Brieﬂy, mammalian cells were plated in 6- or
12-well plates to achieve  40% conﬂuence. The next day,
HiPerFect (Qiagen) was combined with Opti-MEM
medium (Invitrogen) and siRNAs (MWG Biotech).
Before adding to cells, the mixture was left at room tem-
perature for 20min. Sequences of siRNAs targeting SR
proteins, hnRNP I (PTB/nPTB) and scrambled controls
were as we described (6). Sequences of hnRNP A1/A2
siRNAs were also published previously (29).
Visualization of RNA products
Total RNA was extracted with TRI Reagent (Ambion)
and reverse transcribed using oligo-d(T)15 primer, as pre-
viously described (25). Vector-speciﬁc primers PL3 and
PL4 (26) were used for PCR. PCR products were
separated on agarose and polyacrylamide gels and their
signal intensity was measured as described (30).
Antisense oligonucleotides
Splice-switching oligonucleotides (MWG Biotech) were
co-transfected into 293T cells together with the WT and
mutated BTK reporter constructs. Cells were harvested
48h post-transfection. Antisense oligonucleotides (ASOs)
targeted the GC 50ss (BTK-50GC, 50-mG*mG*mA*mA*
mA*mC*mU*mU*mG*mC*mC*mC*mG*mU*mG*
mU*mU*mC*mC*mA) or splicing enhancers between
the authentic and cryptic 50ss (BTK-ESE-M2M3,
50-mG*mU*mU*mG*mC*mA*mA*mA*mU*mU*mU*
mC*mU*mU*mC *mA*mA*mA*mU*mC). Negative
controls included scrambled oligonucleotides (BTK-
50GC-sc, 50-mU*mC*mG*mA*mU*mG*mC*mA*mU*
7078 Nucleic Acids Research, 2011,Vol.39, No. 16mU*mG*mA*mG*mU*mG*mC*mC*mA*mC*mC and
BTK-ESE-M2M3-sc, 50-mG*mU*mA*mC*mA*mU*
mU*mA*mA*mC*mU*mU*mU*mA*mC*mG*mC*mA*
mU*mU), respectively. In these sequences, the letter m
represents an O-methyl modiﬁcation at the second
position of a sugar residue and asterisks denote
phosphorothioates of the RNA backbone. As additional
controls, we employed oligonucleotides with identical
modiﬁcations that target splicing regulatory motifs in
INS intron 1 and their scrambled versions, as described
(ref. 6 and Kralovicova1,J., et al., manuscript in prepar-
ation). Transfections were carried out using jetPRIME
(Polyplus Transfection, Inc.) according to manufacturer’s
recommendations.
Figure 1. Identiﬁcation of aberrant GC 50ss in the BTK gene. (A) Reverse transcription–PCR agarose gel with transcripts from the XLA patient 210/
DACC (P) and an unaffected control (U). M, size marker (500- and 650-nt fragments are denoted by arrowheads); NC, negative PCR control.
Ampliﬁcation of normal (NT) and aberrant (AT) transcripts was carried out with primers C and D in exons 2 and 4. The sizes of NT and AT
fragments are 457 and 564nt, respectively. (B) Sequence chromatograms of AT/NT transcripts. (C) DNA sequencing with primers E (50-ctg gtt gct
taa tcc ctc tt) and F (50-gag atg ttc tga ata tga agg) identiﬁed a single-nucleotide substitution in intron 3 in the XLA patient 210/DACC (P) and his
heterozygous carrier mother, but not in unaffected controls. (D) The BTK minigene construct and schematics of RNA products of the wild-type and
mutated alleles. Exons are shown as boxes, introns as lines. Authentic and aberrant transcripts are shown as dotted and dashed lines, respectively.
The disease-causing T>G mutation is denoted by a star. The alignment of canonical and GC 50ss with U1 snRNA is shown at the top; the improved
base-pairing with U1 snRNA is boxed; the maximum entropy (ME) scores are in parentheses. Predicted BPS of exon 4 is underlined. Tranposable
elements in intron 3 are denoted by horizontal bars, with Alus in gray and LINEs in white; their orientation is indicated by arrowheads. Intron 3
deletion made in the minigene constructs is denoted by a thick line. GAA/CAA trinucleotides in the sequence between aberrant and authentic 50ss are
boxed at the bottom; mutations M1-M5 are shown above; a 76-nt riboprobe for UV crosslinking is shown below as a gray bar. Cloning (A, B) and
ampliﬁcation (C, D) primers are denoted by gray arrows.
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We ampliﬁed a 76-nt DNA fragment (Figure 1D) with
primers T7-BTK-F( 5 0-taa tac gac tca cta tag gga cca atg
tct gag atg ggg a; T7 promoter is italicised) and BTK-R
(50- acc agt cta ttt aca gag aa) using M/M2 plasmid DNAs
as templates. PCR products were gel puriﬁed using the
MinElute kit (Qiagen). Riboprobes were transcribed
using the MAXIScript kit (Ambion) in the presence of
[a-
32P] UTP (800Ci/mmol; PerkinElmer). RNAs were
incubated in 10-ml reaction mixtures containing cytoplas-
mic S100 or HeLa nuclear extracts (4C Biotech), 2mM
MgCl2, 0.5mM ATP, 20mM creatine phosphate and 16U
of RNasin (Promega) at 30 C for 20min. ASOs were
added to the indicated ﬁnal concentration. The samples
were irradiated on ice with a 254-nm ultraviolet (UV)
cross-linker (Ultralum) for 10min and digested with
RNase T1 (0.8U/ml) and RNase A (0.4U/ml) (Ambion)
at 37 C for 20min. Cross-linked proteins were resolved
by 10% sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS–PAGE). Gels were dried, exposed to
phosphor screens and signal intensity was evaluated
using ImageQuant TL software (Amersham).
RNA secondary structure predictions
We used the RNA folding program RNAstructure (v. 5.2),
which accommodates a dynamic programming algorithm
on the principle of minimizing free energy and has an
accuracy of  73% for sequences <700nt (31).
Identiﬁcation of mutation-induced GC 50ss resulting in
genetic disease
Published reports of cryptic and de novo 50ss were
identiﬁed essentially as described (32). We searched
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi),
locus speciﬁc mutation databases (http://www.hgmd.cf.ac
.uk/docs/oth_mut.html), the database of aberrant 50ss
(http://www.dbass.org.uk) (16,33) and home pages of
genetics journals for peer-reviewed reports of
sequence-veriﬁed aberrant transcripts that resulted from
natural disease-causing variants or mutations activating
human GC 50ss. All GC 50ss were manually validated by
mapping the information in the literature to sequences in
the Human Genome project databases.
Validation of the GC 50ss data set
Conserved GC introns were identiﬁed by comparing
human and mouse reference mRNAs and genomic
contigs (http://www.ncbi.nlm.nih.gov/RefSeq/) (Release
40) using GIGOgene engine (http://biigserver.ist
.unomaha.edu/ achurban/GIGOgene/). The non-
canonical splice sites were checked against the human
ASTD database (http://www.ebi.ac.uk/astd/main.html;
release 1.1) and against the Ensembl collection (http://
www.ensembl.org; release 58). Only validated GC 50ss
were analyzed further.
RESULTS
Activation of de novo GC 50ss in the BTK gene
Mutation screening of the gene encoding Bruton’s tyrosine
kinase (BTK) in male patients with XLA (Bruton disease,
MIM 300300) using an RNA-based strategy revealed an
aberrant product (Figure 1A). Sequencing of this cDNA
fragment showed that, as compared to unaffected
controls, the ﬁrst 107nt of intron 3 was inserted between
exons 3 and 4 of the BTK mRNA (Figure 1B). A search
for the underlying mutation in DNA identiﬁed a T>G
transversion at the ﬁrst position of the shortened intron,
creating a noncanonical 50ss (Figure 1C). The new
GC-AG intron was of the U2-type as it lacked typical
U12-type motifs, including BPS. Although the remaining
positions of the de novo GC 50ss showed a better match to
U1 snRNA, the estimated strength of this 50ss was con-
siderably weaker than its authentic counterpart
(Figure 1D, top left), yet the latter splice site was efﬁcient-
ly repressed in vivo.
Identiﬁcation of disease-causing GC 50ss and
characterization of their intrinsic strength
To begin addressing the question of why a weak de novo
50ss in BTK was used instead of the intact and strong au-
thentic site nearby, we ﬁrst looked for previously pub-
lished disease-causing GC 50ss. We identiﬁed additional
11 cases (Table 1), with only two in introns (refs. 34, 35
and this study). Apart from the GC 50ss that employed
authentic 30ss, GC 50ss were reported for three
disease-causing cryptic exons that were activated in
introns of the ATM (36), NF1 (37) and LHCGR (38)
genes.
Examination of the intrinsic strength of the GC 50ss
showed that their average maximum entropy (ME) score
(39) was much lower than for their authentic GT equiva-
lents (medians 2.33 versus 8.24; P<0.001, Mann–Whitney
rank sum test). This score, which best discriminated au-
thentic and aberrant 50ss (16), was, with one exception,
always lower for GC 50ss than for their authentic equiva-
lent (Table 1). Interestingly, both the calculated free
energy and the number of hydrogen bonds with U1
snRNA were higher in 4 of 12 GC 50ss than in their GT
counterparts, with free energy showing a signiﬁcant differ-
ence between the two groups of splice sites (P=0.035).
This supports the compensatory role of base-pairing inter-
actions with U1 snRNA in efﬁcient GC 50ss activation.
Intrinsically strong adjacent splice sites facilitate
activation of weak GC 50ss
Inspection of splice sites ﬂanking the aberrant GC 50ss in
BTK intron 3 showed that the 30ss of this intron was very
strong (ME score 9.0), with a long polypyrimidine tract
and a well-deﬁned BPS (Figure 1D, top). Computation of
the intrinsic strength of all disease-causing aberrant 50ss
and their authentic neighbors showed that splice sites
adjacent to aberrant GC 50ss tended to be stronger than
the average (Figure 2A), with a signiﬁcant difference in the
means for the 50ss of downstream but not upstream
introns. This suggests that efﬁcient inclusion of these
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Nucleic Acids Research, 2011,Vol.39, No. 16 7081aberrant exons in mRNAs may require help from ﬂanking
splice sites and that the 50ss immediately downstream
could be of a particular importance.
Comparisons of authentic GC and GT 50ss
To see if similar differences can be found for natural
human GC and GT introns, we compiled sequences of
500 natural GC 50ss that were annotated in Ensembl/
ASTD (Supplementary Table S1). The number of unique
9-nt GC 50 ss sequences was 101, with 28 exonic and 40
intronic (excluding the ﬁrst two intron positions)
combinations.
As expected, the mean ME score of the validated GC
50ss data set was signiﬁcantly lower than a similar number
(n=457) of authentic GT counterparts of pathogenic GT
50ss (2.36 versus 7.60; P<0.0001, t-test). The mean
number of hydrogen bonds was also lower for existing
GC sites than for GT counterparts (means 6.9 versus
7.1, P<0.002, t-test, Supplementary Table S1). Even
more signiﬁcant P values were observed for the Shapiro
and Senapathy scores (75.4 versus 80.1, P<0.0001) and
free energy (G) values ( 4.0 versus  5.7, P<0.0001).
Although the tendency for higher scores of ﬂanking
splice-sites was similar to disease-associated GC splice
sites (compare Figure 2A and B), the observed differences
failed to reach strict statistical signiﬁcance. This compari-
son suggests that, in addition to stronger afﬁnity to U1
snRNA, efﬁcient splicing of existing GC introns requires
other, more critical signals.
Role of auxiliary splicing sequences in activation of
GC 50ss
The GC 50ss in BTK intron 3 is intrinsically much weaker
than its authentic equivalent, yet it was used by the
majority of transcripts (Figure 1A), suggesting that it is
promoted by splicing enhancers and/or the authentic
neighbor is repressed by silencers. Interestingly, inspection
of the newly exonized segment revealed an unusually high
number of GAA and CAA trinucleotides (Figure 1D). The
former elements are potent exonic enhancers while the
latter motifs activate exon inclusion to a lesser extent
(40–42). The GAA/CAA-containing enhancers show a
bias toward single-stranded RNA segments both in
natural exons (43) and in pseudoexons activated by patho-
genic intronic mutations (42). The frequency of GAA
elements in the newly exonized BTK segment was
 3-times higher than in average introns (4.67% versus
1.76%) and  2-times higher than in existing human
exons (versus 2.36%) (42). The density of CAA
trinucleotides was also higher (2.80% versus 1.55%/
1.94%, respectively).
Table 2 shows densities of predicted enhancers and si-
lencers in newly exonized and intronized segments for
disease-causing aberrant GC 50ss and their authentic
counterparts. The density of enhancers in the exonized
sequences was higher than in existing introns and, in the
Figure 2. Comparison of the predicted strength of disease-causing GC
50ss and their authentic counterparts. GC and GT 50ss are denoted by
black and gray columns, respectively. (A) Disease-causing aberrant GC
50ss. (B) Authentic human GC 50ss. The predicted strength was
computed as the maximum entropy (ME) score (16,39,86). Error bars
represent standard deviations (SD). Corresponding splice sites are sche-
matically shown in the lower panels where the GC 50ss is boxed.
Table 2. Average densities of predicted auxiliary splicing motifs in exonized and intronized segments upon activation of GC 50ss by pathogenic
mutations
RESCUE-ESE
density
PESE
density
EIE score
density
SF2/ASF ESE
score density
PESS
density
FAS-ESS
density
Exonized intronic segments 8.33 8.48 504.73 9.69 0 2.07
Intronized exonic segments 4.56 6.45 298.40 15.44 1.58 2.35
Average human introns 7.47 3.41 340.03 9.16 4.66 5.76
Average human exons 10.91 7.00 470.97 14.15 1.34 2.86
Densities of each predicted auxiliary splicing motif in newly intronized and exonized segments were obtained as described previously (25,104).
Densities in existing human exons and introns were determined previously (25) and are shown here for comparison.
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and exon identity elements (EIEs) (45), even higher than
in average exons. Conversely, the enhancer densities in
intronized segments were lower than in average exons.
By contrast, the density of silencers in exonized
segments was lower than that in existing introns or even
average human exons while intronized segments had a
higher density of putative exonic splicing silencers
(PESSs) (44), but not silencers determined by a
ﬂuorescence-activated screen (FAS-ESSs) (46).
At the level of individual nucleobases, intronized se-
quences of GC exons had a lower frequency of adenines
(Figure 3A–C), which may reﬂect a critical importance of
(di)adenosines for tertiary interactions in large RNAs and
their role in exon recognition. In addition, these sequences
were also cytosine- and guanine-rich, with the GC-content
higher in natural GC exons as compared to GT exons
(Figure 3C). We also observed a loss of uracil and gain
of guanine in exonized intronic sequences (Figure 3). The
frequency of non-overlapping G triplets in intronized
segments was 1.41% as compared to 1.12% in exons
and 1.24% in introns, but was somewhat higher for
exonized segments (1.65%). Finally, Figure 4 shows the
density of auxiliary splicing elements in conserved GC and
GT exons. Mean densities of PESEs and putative SF2/
ASF ESEs were particularly enriched in GC exons as
compared to conserved GT exons, speculatively reﬂecting
a possible preference of this SR protein for 50ss (47,48).
Identiﬁcation of a splicing enhancer of the BTK GC 50ss
To test if activation of the weak GC 50ss is indeed induced
by high-density GAA/CAA-type enhancers in the newly
exonized segment we constructed a three-exon minigene
reporter with and without the disease-causing substitution
and designed ﬁve mutations (M1–M5) that reduce the
number of GAAs (M1–M4) or CAAs (M5) to the level
typical of average introns. We swapped the ﬁrst and
second positions of GA or CA dinucleotides in these
elements to remove diadenosines, which are frequently
involved in intra- and intermolecular interactions of
large RNAs (refs. 42, 49 and 50 and references therein),
while keeping the overall nucleotide composition un-
changed. Splicing of the WT minigenes produced canon-
ical mRNAs, with minor species spliced to a dual splice
site (30ss at the 50ss of the last exon) activated by the
adjacent EcoRI cloning site, both in the 293T cells and
a B-cell line Nalm-6 (Figure 5A and B, lane 1). The
reporter construct with the T>G transversion (M) ex-
hibited splicing to the GC 50ss in  90% primary tran-
scripts (Figure 5A and B, lane 2), recapitulating the
in vivo splicing pattern. A major reduction of aberrant
splicing was observed for M2 and M3 mutants
(Figure 5C and D), each removing one of the tandem
GAA elements located in the middle of the exonized
segment. This (GAA)2 element was conserved in Great
Apes and Old World Monkeys while the 9-nt signal of
the GC 50ss was more relaxed in Homininae and more
Figure 3. Nucleotide composition of intronized exonic and exonized
intronic segments. (A) Disease-associated GC 50ss (a total of 881nt).
(B) Disease-associated GT 50ss (36 378nt). (C) Authentic GC (n=500)
and GT (n=44232) human exons are shown together with a sample of
2309 intronic pseudoexons in the 50 untranslated region (44) for
comparison.
Figure 4. Density of auxiliary splicing elements in human GC and GT
exons. Comparison of the mean densities of FAS-ESSs (46), PESSs/
PESEs (44), EIEs (45), RESCUE-ESEs (87,88) and putative SF2/ASF,
SC35, SRp40 and SRp55 ESEs (89,90) in 500 GC and 44232 GT
exons. ****P<0.0001; ***P<0.001; **P<0.01; *P<0.05 (unpaired
t-tests). Element densities were calculated for each input sequence as
described previously (25); EIE densities are shown as 1/100 of their
actual values. Error bars indicate SD.
Nucleic Acids Research, 2011,Vol.39, No. 16 7083stringent in lower primates due to an A>G transition
(Supplementary Figure S1). Mutation M4, which was
close to the GC 50ss, had only a minor effect. Mutation
M5, which removed an apparently weaker CAA element,
decreased aberrant splicing by a third. By contrast,
mutation M1, which is adjacent to a G triplet, increased
splicing to cryptic 50ss. Thus, the strongest support of GC
50ss splicing was provided by the conserved (GAA)2
element.
Efﬁcient inhibition of aberrant GC 50ss by
splice-switching oligonucleotides
To reduce cryptic splicing and provide further evidence for
the importance of the (GAA)2-containing intronic
enhancer, we have employed ASOs designed to block
access of the spliceosomal machinery to the GC 50ss and
M2/M3. Uniform phosphorothioate oligoribonucleotides
that had 20-O-methyl modiﬁcation at each base efﬁciently
repressed the GC 50ss in a dose-dependent manner (Figure
5E), with oligos targeting the GC 50ss exhibiting signiﬁ-
cant repression at a ﬁnal concentration of only 1nM
(Supplementary Figure S2). A major reduction of cryptic
splicing was observed even in the absence of transfection
reagent (lane T-, Figure 5E). By contrast, scrambled oligos
and their mixture failed to inhibit the inclusion of the
intron 3 segment in mRNA (Figure 5E and data not
shown). At higher concentrations, each oligo as well as
their scrambled counterparts induced exon 3 skipping
while repressing splicing to the dual splice site that
separated the last minigene exon from the cloning
EcoRI site. Thus, the aberrant splicing phenotype in this
XLA case was effectively repaired by chemically modiﬁed
oligonucleotides targeting either the GC 50ss itself or the
enhancer, providing the ﬁrst example of a successful cor-
rection of the pathogenic GC 50ss activation.
Trans-acting factors associated with the GC 50ss
selection in BTK intron 3
To identify proteins that bind the critical enhancer motif,
we ﬁrst examined splicing of M, M2 and M3 constructs in
cells depleted of/overexpressing a series of cellular factors
known to inﬂuence RNA processing, as we described
earlier (6). We found that depletion of SR proteins 9G8,
SC35 and Tra2a/b decreased utilization of cryptic GC 50ss
on each reporter pre-mRNA (Figure 6A and B). By
contrast, overexpression of these factors was associated
with almost exclusive use of this splice site (Figure 6C).
Overexpression of SF2/ASF promoted exon 3 skipping
(Figure 6C and D). Exon 3 skipping was also observed,
albeit to a lesser extent in cells overexpressing SRp20 and
SC35 but not Tra2b (Figure 6C), despite efﬁcient
downregulation and overexpression of this factor in trans-
fected cells (Figure 6E).
To identify proteins that bind the (GAA)2 enhancer, we
carried out UV-RNA crosslinking with the BTK-PY7
versions of M, M2 and M3 constructs (Figure 7A).
Splicing of each construct in 293T and HeLa cells
replicated the M>M3>M2 hierarchy observed for authen-
tic clones (compare Figures 7B and 5C), indicating that
the tandem GAA element plays a critical role also in
splicing of hybrid reporters. The transcripts from each
clone could be spliced in nuclear extracts (Figure 7C);
however, the pattern of proteins crosslinked to uniformly
labeled RNAs was similar (Figure 7D). The UV
crosslinking of short, internally labelled RNA probes
carrying M and M2 and spanning 71% of the exonized
segment (Figure 1D, bottom) also revealed a comparable
set of proteins, with the exception of a weaker 55-kDa
fragment which was more pronounced for the M construct
(Figure 8A). Secondary structure predictions suggested
that both M and M2 maintain a relatively stable hairpin
with a terminal purine tetraloop and an A/U repeat as
loop-closing base pairs (Figure 8B). This motif may
Figure 5. Efﬁcient activation of the GC 50ss in BTK intron 3 requires a
GAA intronic enhancer. The splicing pattern of BTK minigene report-
ers in 293T (A, C) and Nalm-6 (B) cell lines. Designation of the
reporter constructs is at the top, RNA products are to the right and
percentage of splicing to the GC 50ss (%AT) is at the bottom. WT, wild
type reporter construct; M, construct with the T>G transversion; M1–
M5 mutations and deletion of interspersed repeats (Del) are shown in
Figure 1D. (D) Summary of the triplicated transfection experiment.
Error bars represent SD. (E) Effective repression of aberrant splicing
by antisense oligonucleotides (ASOs) targeting the GC 50ss itself or the
upstream M2/M3 enhancer (ESE). The ﬁnal concentration of each ASO
was 20, 50, 100 and 200nM. SC, an equimolar mix of scrambled
controls of the two ASOs; C1, a generic negative control at 200nM,
T-, equimolar amounts of GC 50ss and ESE ASOs (at 100nM each)
added to cells without any transfection reagent. No-transfection,
no-template and no-RT controls are not shown. RNA products are
to the right and the percentage of splicing to the GC 50ss (%AT) is
at the bottom. The lowest effective ASO concentrations were
determined in a separate experiment shown in Supplementary
Figure S1.
7084 Nucleic Acids Research, 2011,Vol.39, No. 16serve as a potential binding site for poly(Y)-proteins, such
as  57-kDa hnRNP I (PTB). However, downregulation
of PTB and nPTB proteins in 293T cells failed to alter the
relative expression of RNA products (Figure 8C). Taken
together, SR proteins 9G8, SC35 and Tra2a/b were
associated with pathogenic activation of the GC 50ss in
BTK intron 3.
Transposable elements and GC 50ss activation
BTK intron 3 is  2.8kb long, but >2.0kb of its
mid-portion is formed by a continuous tract of transpos-
able elements (TEs), consisting of several Alu insertions in
a single long interspersed nuclear element (Figure 1D).
Alus in the opposite orientation would be predicted to
create base-pairing interactions that may inﬂuence
splicing efﬁciency of adjacent segments (51,52) and may
promote or repress the aberant GC 50ss. In particular,
short interspersed nuclear elements (SINEs), including
Alus and mammalian interspersed repeats (MIRs), may
provide favorable substrates for activation of splice sites
and cryptic exons (42,52–54). To test if the TE stretch can
inﬂuence the GC 50ss splicing, we deleted this sequence
from intron 3 and examined exogenous transcripts follow-
ing transient transfections into several cell lines. However,
splicing was not altered by this deletion (Figure 5A and B,
lanes 3 and 4) and repeated attempts to delete one or
more AluSx in the opposite orientation, predicted to
form a double-stranded structure of extreme stability
( 487.3kcal/mol), were not successful.
We also examined repetitive sequences ﬂanking each
disease-associated GC 50ss, but we found no aberrant
GC 50ss that would be activated in recognizable TE frag-
ments. The average distance from the nearest TE (L2/L3
fragments in ﬁve cases, DNA transposons in four cases
and SINEs in two cases) was  620nt. Extension of this
analysis to authentic GC exons and intronic sequences
Figure 6. Splicing factors associated with promotion or repression of the GC 50ss in BTK intron 3. (A) RNA interference-mediated depletion of
proteins shown at the top in 293T cells. SC47%, SC68%, scrambled control siRNAs with the indicated GC contents. RNA products are to the right,
the reporter is at the bottom. Individual depletion of Tra2a and Tra2b proteins (the ofﬁcial gene symbol TRAB) is shown in panel B. (B) Summary
of the triplicated transfection experiment with M, M2 and M3 constructs. Error bars represent SD. (C) Overexpression of SF2/ASF, SRp20, 9G8,
SC35 and Tra2b in 293T cells. BTK reporter constructs are to the left, RNA products to the right. GFP, plasmid expressing green ﬂuorescent
protein. Tra2b here refers to the longest isoform designated Tra2b1 (82). (D) Sequence chromatogram showing BTK exon 3 skipping in 293T cells
overexpressing SF2/ASF and SRp20. (E) Western blot analysis of Tra2b and 9G8 proteins. Antibodies against Tra2b and b-actin were purchased
from Abcam (ab31353 and ab37063, respectively), antibodies against 9G8 (SFRS7) were obtained from Sigma (SAB1101226). NE, nuclear extracts;
1/4, loading of the lysate was reduced by 75% as compared to untreated 293T cells. Overexpressed Tra2b and 9G8 were fused with GFP and T7
tags, respectively. Size markers are shown to the left. Antibodies against SC35 (ab28428) failed to yield speciﬁc bands, but the increased and
decreased expression was observed using quantitative RT–PCR with RNA samples from transfected cells (data not shown).
Nucleic Acids Research, 2011,Vol.39, No. 16 7085adjacent to GC 50ss revealed several examples of
TE-derived GC 50ss (Supplementary Figure S3).
Speciﬁcally, PSD4 exon 3 and FBXO18 exon 2 originated
from sense MIRc, GC 50ss in PTR, DDX52, AGBL2 and
AP3M1 exons from Alus, and NAT1, GLYATL1 and
BAZ1A exons from LTR retrotransposons. Both GC
50ss in PSD4 and FBXO18 mapped to identical positions
in the sense MIR consensus and colocalized with at least
three GT 50ss (42).
Analysis of the ﬁrst TEs downstream of the GC 50ss
revealed that SINEs were clearly overrepresented
(>60%, Figure 9A). The distance between GC 50ss and
these TEs was the largest for Alus (mean 608nt) and
smallest for LTRs (206nt) (Figure 9B). This difference
was greater than would be expected by chance
(P=0.03, Kruskal–Wallis one-way analysis of variance
on ranks), suggesting that the Alu proximity to splice
sites may interfere with selection of weaker 50ss, most
likely through Alu-formed pre-mRNA structures and/or
their binding properties.
DISCUSSION
Choice of authentic splice sites among a large excess of
similar consensus signals in primary transcripts is
governed by multiple decisions of the spliceosomal
machinery that are at present poorly understood.
Focusing on a group of noncanonical 50ss that provide
natural models of weak splice-site activation in vivo, our
study has characterized compensatory signals associated
with selection of pathogenic GC 50ss. Although these 50ss
appear to signify a relaxation of splice site motifs in higher
eukaryotes, which enhances regulatory potential of gene
expression pathways (55), the fraction of natural GC-AG
introns is much higher in some lower organisms, particu-
larly those with high genome GC content, approaching
40% in a pelagophyte A. anophagefferens (56). It is not
clear why this frequency is as high and if there is any
special function of this peculiar choice of the 50 intron
end as compared to other organisms. Mammalian GC
50ss can play a role in coupled splicing and translation
control as well as in subcellular localization.
For example, in the mouse Gli1 oncogene, a terminal tran-
scriptional effector of the hedgehog signaling pathway, the
GC 50ss promoted exon 1B skipping and translation efﬁ-
ciency (57). Subcellular localization and degradation of
ING4, a cell growth repressor, was controlled by alterna-
tive splicing of the GC(N)7GT exon (58).
An additional level of GC 50ss regulation can be
provided by RNA editing, which has been shown to
modulate choice of GT 50ss (59) and 30ss (60,61).
Figure 8. UV-RNA crosslinking of exonized pre-mRNA of BTK
intron 3. (A) UV crosslinking of M and M2 RNAs in cytoplasmic
S100 and nuclear extracts. (B) Predicted hairpins of M and M2
riboprobes. (C) Splicing of BTK constructs in 293T cells depleted of
PTB/nPTB. RNA products are shown schematically to the right,
reporter constructs at the bottom and siRNAs at the top. SC47%/
SC68%, control siRNAs with the indicated GC content. Final concen-
tration of siRNAs targeting PTB (91) was 70nM. Final concentration
of each siRNA targeting nPTB (92) was 15nM.
Figure 7. UV-RNA crosslinking of hybrid BTK-PY7 constructs.
(A) Schematic representation of the hybrid BTK-PY7 reporter. The
length of introns (lines) and exons (boxes) is to a scale shown at the
bottom. Restriction enzymes are shown at the top. The position of GC
50ss-activating mutation is denoted by a star. (B) Splicing pattern of the
hybrid BTK-PY7 reporters in HeLa cells. (C) Splicing of BTK-PY7
reporters in HeLa nuclear extracts. Mutations are shown at the
bottom; P, mock treated riboprobe; splicing products are to the right.
Final concentration of ASOs was 2, 20 and 200nM. (D) UV-RNA
crosslinking of BTK-PY7 reporter constructs (at the top). The size of
crosslinked proteins is to the left.
7086 Nucleic Acids Research, 2011,Vol.39, No. 16Although this has not been formally shown for GC 50ss to
our knowledge, editing of adenosine to inosine, which is
recognized as guanosine by the spliceosome, might create
the 50ss GC (AC>IC) and either improve or impair the
50ss consensus. For example, a CAG/GCAAAU>CAG/
GCAAIU editing change would increase the ME score
from 1.0 to 3.1, while a CAG/GCGAGU>CAG/
GCGIGU change would reduce it from 2.9 to 0.8. Both
adenosine-to-inosine and cytosine-to-uridine editing
events may also alter auxiliary splicing sequences
required for exon recognition, as was shown for an Alu-
derived splicing enhancer in the gene coding for prelamin
A (61). Because GC 50ss are on average weaker than GT
50ss (Figure 2) and rely more on splicing silencers and
enhancers (Figure 4), editing events within these motifs
would be expected to have a stronger inﬂuence on recog-
nition of GC 50ss than GT 50ss. Our search of the database
of human editing sites (62) has identiﬁed several examples
of adenosine-to-inosine editing in the proximity of exons
with GC 50ss (Supplementary Table S2). The importance
of these editing sites in splicing can be tested can be tested
experimentally in future studies. Although creation of GC
50ss by RNA editing could be excluded in our BTK case
(Figure 1), coupled editing and alternative splicing of GC
50ss would represent a particularly ﬁne instrument for
spatiotemporal regulation of gene expression, which
warrants a more systematic investigation in the future.
The association of GC 50ss with stronger adjacent splice
sites (Figure 2) is in agreement with previous observations
of splicing interdependence of neighboring introns.
Exon-skipping splice-site muations often lead to deletion
of more than one exon in both directions, and the same
applies to intron retention events (63,64). Selection of
adjacent 30ss (30) and 50ss (65) can also be inﬂuenced by
unproductive splicing, presumably by recognizing decoy
30ss and 50ss to which spliceosomal components are at-
tracted, which then facilitates recruitment of additional
factors. Kinetic analyses demonstrated that an upstream
competing 50ss enhances the rate of intron-proximal
splicing (65). Alternatively, decoy 50ss may resemble aux-
iliary splicing elements that are abundant in exons and
introns and may shape intramolecular interactions and/
or binding gamut (30,65,66).
The U1 binding potential for GC 50ss seems to be an
important predictor of their activation (Supplementary
Table S1), consistent with previous correlation of the
observed rates of 50ss splicing with their U1 binding
potential (65). A mutant U1 activated a noncanonical
cryptic 50ss in Schizosaccharomyces pombe even in the
presence of a wild-type sequence at the natural 50
junction, suggesting that snRNAs redirected splicing via
base-pairing (67).
Weak or low-complementarity splice sites are expected
to be less efﬁciently included in mature transcripts. The
intrinsic strength of BTK splice sites and auxiliary
elements (Supplementary Table S3) suggested that the
30ss of exon 14 and the 50ss of exon 15 are exceptionally
weak. Similarly, exons 16–18 lack enhancers or had an
excess of silencers, which makes them more susceptible
to skipping than the remaining exons. In fact, character-
ization of aberrant transcripts in puriﬁed pre-B leuke-
mia cells clearly showed that these exons were
preferentially skipped (68), which probably resulted from
subphysiological conditions during cell puriﬁcation, rather
than from BTK-mediated processes contributing to malig-
nant transformation. Thus, exons that are more likely to
exhibit skipping in stressed cells are predictable ab initio,
which should be taken into account in experimental
studies. Recently developed online tools predicting
exonic positions/substitutions that result in skipping of
the exon provide merely a starting point toward more de-
ﬁnitive and practical algorithms (69).
It was surprising to see the excess of predicted enhancers
in exonized segments and their lack in intronized segments
(and vice versa) with such a small sample size of
disease-associated events (Table 2). For example, the
EIE score density was 1.96 higher in exonized intronic
segments than for those activated as a result of aberrant
GT 50ss. Collectively, our data suggest that recognition of
GC 50ss requires a stronger set of auxiliary elements that
compensate weak splice sites and promote high-level usage
required for manifestation of a recognizable phenotype.
These results should ultimately improve computational
prediction of GC 50ss. For example, a recently updated
SpliceScan II, which outperformed other GC 50ss sensors
based on weight matrices (70), did not identify the BTK
GC 50ss on the mutated allele (Supplementary Figure S4).
Giving more weight to auxiliary elements should improve
sensitivity of prediction algorithms that attempt to
identify pathogenic GC 50ss.
Figure 9. Transposable elements and selection of GC 50ss.
(A) Frequencies of TE families in 500 GC introns, among the ﬁrst
TEs downstream of the GC 50ss and the overall frequency in the
human genome (93) for comparison. (B) The average distance
between the GC 50ss and the 50-end of the ﬁrst downstream TE. TE
families are shown at the bottom.
Nucleic Acids Research, 2011,Vol.39, No. 16 7087In our experimental model of GC 50ss activation, we
identiﬁed 9G8, Tra2a/b, SF2/ASF and SC35 as proteins
important for selection of this splice site (Figure 6A and
data not shown). Tra2b has been previously shown to bind
purine-rich elements, including GAA repeats (71–75) and
also remains a prime candidate for binding to the pre-
dicted terminal loop (Figure 8B), probably in a complex
with other SR proteins. The AGAA motif appears to be
an optimal binding site of Tra2b that lacks the arginine/
serine-rich domain, and was superior to NGAA or UCAA
(76,77). The weaker afﬁnity for CAA trinucleotides is
likely to reﬂect cytidine deﬁciency to ﬁx the ﬁrst adenosine
on the b sheet surface of Tra2b (76). This interaction may
account for least partially account for a lower activity of
C/A-rich splicing enhancers than their G/A-containing
equivalents (41,42), although the involvement of other
proteins cannot be excluded. Drosophila Transformer 2
protein partners include B52/SRp55 and Rbp1/SRp20
(78); in our experiments SRp20 depletion promoted the
GC 50ss use in each reporter pre-mRNA (Figure 6A and
B). Although site-speciﬁc labeling was not carried out, we
observed no M- or M2/M3-speciﬁc proteins under splicing
conditions on crosslinking gels (Figures 7D and 8A),
keeping open the possibility that the loop is primarily
involved in tertiary interactions to an unknown RNA
receptor. In large RNAs, such contacts are often
mediated by diadenosines, with the A-minor motifs
docking into the minor groove of a receptor helix as
probably the most frequent tertiary contacts (50,79).
Secondary structure predictions of 76-nt riboprobes
showed that the terminal purine tetraloop in WT/M was
also maintained for M2 (Figure 8B), but not M3. This
may explain a smaller size of M3 transcripts on native
polyacrylamide gels (Figures 5C and 7B), as their
sequence analysis excluded cryptic splicing. By contrast,
although the GAAG tetraloop was predicted for the M
version of BTK-PY7 pre-mRNA, the M2 and M3 motifs
in the hybrid clone would rather reside in internal bulges/
loops or double-stranded conformation (data not shown).
Unlike G triplets that appear to act additively and are less
context-sensitive (6,80), individual GAA/CAA elements
located in the exonized segment of BTK had more
variable effects on splice site selection (Figure 5D). This
is likely to reﬂect structural constraints of their respective
ligands or their high dependency on adjacent sequences.
Finally, BTK exon 3 provides yet another example of an
exon negatively regulated by SF2/ASF (Figure 6C and D),
as reported earlier for splicing of the adenovirus IIIa
pre-mRNA (81) and human substrates, including
TRA2B exon 2 (82) and CFTR exon 9 (83).
Our analysis of TEs around GC 50ss further supported a
special role of Alus in exonization of intronic sequences.
Apart from supplying strong polypyrimidine tracts and
both 30ss and 50ss (53,54,84), Alus contain splicing enhan-
cers (61,85) and silencers (30). The latter may be directly
linked to the observed lack of these elements in the vicinity
of GC 50ss and this repression of splice site selection may
be further modiﬁed by RNA editing. Although we could
not test this in our BTK model in which Alus inserted in a
more ancient repeat hampered DNA manipulation
(Figure 1D), future studies should address this hypothesis.
In conclusion, we have developed a new experimental
model for activation of a pathogenic GC 50ss (Figures 1
and 5), identiﬁed cis-elements and SR proteins positively
and negatively associated with this event (Figures 5 and 6),
and showed that the aberrant splicing can be corrected
in vitro and ex vivo (Figure 5 and Supplementary
Figure S2). Systematic characterization of both disease-
causing and authentic GC 50ss revealed a series of charac-
teristics associated with their efﬁcient activation, explain-
ing why such intrinsically weak sites are used in the
vicinity of strong authentic equivalents and facilitating
their better prediction in human genetic disorders.
Finally, the ever-increasing collection of disease-linked
aberrant splice sites (33) provides a simple yet powerful
means of studying intricate rules that govern human
splice-site selection in vivo.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
We thank D. Black, UCLA, G. Dreyfuss, HHMI, C.
Smith, University of Cambridge, A. Krainer, Cold
Spring Harbor Lab, M. Hastings, University of Chicago,
G. Screaton, Imperial College, J. Ca ´ ceres, University of
Edinburgh, and I. Eperon, University of Leicester, for
providing antibodies/plasmids or useful discussions. We
also thank L. Tricas, Hospital Universitario Central de
Asturias, for providing the patient’s blood sample,
J. Rogers for critically reading the manuscript and an-
onymous reviewers for helpful comments.
FUNDING
The Juvenile Diabetes Research Foundation
International, Diabetes UK (to I.V.); the Swedish
Research Council, the European Union FP7-HEALTH-
2008-223293 grant ‘‘European genetic disease diagnos-
tics’’; and the Stockholm County Council (to E.S.).
Funding for open access charge: the Swedish Research
Council.
Conﬂict of interest statement. None declared.
REFERENCES
1. Wahl,M.C., Will,C.L. and Lu ¨ hrmann,R. (2009) The spliceosome:
design principles of a dynamic RNP machine. Cell, 136, 701–718.
2. Burge,C.B., Tuschl,T. and Sharp,P.A. (1999) In Gesteland,R.F.,
Cech,T.R. and Atkins,J.F. (eds), The RNA World. Cold Spring
Harbor Laboratory Press, New York, pp. 525–560.
3. Buratti,E., Muro,A.F., Giombi,M., Gherbassi,D., Iaconcig,A. and
Baralle,F.E. (2004) RNA folding affects the recruitment of SR
proteins by mouse and human polypurinic enhancer elements in
the ﬁbronectin EDA exon. Mol. Cell. Biol., 24, 1387–1400.
4. Warf,M.B. and Berglund,J.A. (2010) Role of RNA structure in
regulating pre-mRNA splicing. Trends Biochem. Sci., 35, 169–178.
5. Zhang,X.H. and Chasin,L.A. (2006) Comparison of multiple
vertebrate genomes reveals the birth and evolution of human
exons. Proc. Natl Acad. Sci. USA, 103, 13427–13432.
7088 Nucleic Acids Research, 2011,Vol.39, No. 166. Kralovicova,J. and Vorechovsky,I. (2010) Allele-dependent
recognition of the 30 splice site of INS intron 1. Hum. Genet.,
128, 383–400.
7. Zhuang,Y. and Weiner,A.M. (1986) A compensatory base change
in U1 snRNA suppresses a 50 splice site mutation. Cell, 46,
827–835.
8. Bruzik,J.P. and Steitz,J.A. (1990) Spliced leader RNA sequences
can substitute for the essential 50 end of U1 RNA during splicing
in a mammalian in vitro system. Cell, 62, 889–899.
9. Crispino,J.D., Blencowe,B.J. and Sharp,P.A. (1994)
Complementation by SR proteins of pre-mRNA splicing reactions
depleted of U1 snRNP. Science, 265, 1866–1869.
10. Zhong,X.-Y., Wang,P., Han,J., Rosenfeld,M.G. and Fu,X.-D.
(2009) SR proteins in vertical integration of gene expresion from
transcription to RNA processing to translation. Mol. Cell, 35,
1–10.
11. Moore,M.J. and Proudfoot,N.J. (2009) Pre-mRNA processing
reaches back to transcription and ahead to translation. Cell, 136,
688–700.
12. Thanaraj,T.A. and Clark,F. (2001) Human GC-AG alternative
intron isoforms with weak donor sites show enhanced consensus
at acceptor exon positions. Nucleic Acids Res., 29, 2581–2593.
13. Burset,M., Seledtsov,I.A. and Solovyev,V.V. (2000) Analysis of
canonical and non-canonical splice sites in mammalian genomes.
Nucleic Acids Res., 28, 4364–4375.
14. Sheth,N., Roca,X., Hastings,M.L., Roeder,T., Krainer,A.R. and
Sachidanandam,R. (2006) Comprehensive splice-site analysis using
comparative genomics. Nucleic Acids Res., 34, 3955–3967.
15. Churbanov,A., Winters-Hilt,S., Koonin,E.V. and Rogozin,I.B.
(2008) Accumulation of GC donor splice signals in mammals.
Biol. Direct, 3, 30.
16. Buratti,E., Chivers,M.C., Kralovicova,J., Romano,M., Baralle,M.,
Krainer,A.R. and Vorechovsky,I. (2007) Aberrant 50 splice sites in
human disease genes: mutation pattern, nucleotide structure and
comparison of computational tools that predict their utilization.
Nucleic Acids Res., 35, 4250–4263.
17. Dou,Y., Fox-Walsh,K.L., Baldi,P.F. and Hertel,K.J. (2006)
Genomic splice-site analysis reveals frequent alternative splicing
close to the dominant splice site. RNA, 12, 2047–2056.
18. Jackson,I.J. (1991) A reappraisal of non-consensus mRNA splice
sites. Nucleic Acids Res., 19, 3795–3798.
19. Mount,S.M. (2000) Genomic sequence, splicing, and gene
annotation. Am. J. Hum. Genet., 67, 788–792.
20. Kitamura-Abe,S., Itoh,H., Washio,T., Tsutsumi,A. and
Tomita,M. (2004) Characterization of the splice sites in GT-AG
and GC-AG introns in higher eukaryotes using full-length
cDNAs. J. Bioinform. Comput. Biol., 2, 309–331.
21. Burset,M., Seledtsov,I.A. and Solovyev,V.V. (2001) SpliceDB:
database of canonical and non-canonical mammalian splice sites.
Nucleic Acids Res., 29, 255–259.
22. Abril,J.F., Castelo,R. and Guigo,R. (2005) Comparison of splice
sites in mammals and chicken. Genome Res., 15, 111–119.
23. Aebi,M., Hornig,H. and Weissmann,C. (1987) 50 cleavage site in
eukaryotic pre-mRNA splicing is determined by the overall 50
splice region, not by the conserved 50 GU. Cell, 50, 237–246.
24. Vetrie,D., Vorechovsky,I., Sideras,P., Holland,J., Davies,A.,
Flinter,F., Hammarstro ¨ m,L., Kinnon,C., Levinsky,R., Bobrow,M.
et al. (1993) The gene involved in X-linked agammaglobulinaemia
is a member of the src family of protein-tyrosine kinases. Nature,
361, 226–233.
25. Kralovicova,J. and Vorechovsky,I. (2007) Global control of
aberrant splice site activation by auxiliary splicing sequences:
evidence for a gradient in exon and intron deﬁnition.
Nucleic Acids Res., 35, 6399–6413.
26. Kralovicova,J., Houngninou-Molango,S., Kra ¨ mer,A. and
Vorechovsky,I. (2004) Branch sites haplotypes that control
alternative splicing. Hum. Mol. Genet., 13, 3189–3202.
27. Deirdre,A., Scadden,J. and Smith,C.W. (1995) Interactions
between the terminal bases of mammalian introns are retained
in inosine-containing pre-mRNAs. EMBO J., 14, 3236–3246.
28. Heinonen,J.E., Smith,C.I. and Nore,B.F. (2002) Silencing of
Bruton0s tyrosine kinase (Btk) using short interfering RNA
duplexes (siRNA). FEBS Lett., 527, 274–278.
29. Kashima,T. and Manley,J.L. (2003) A negative element in SMN2
exon 7 inhibits splicing in spinal muscular atrophy. Nat. Genet.,
34, 460–463.
30. Lei,H. and Vorechovsky,I. (2005) Identiﬁcation of splicing
silencers and enhancers in sense Alus: a role for pseudo-acceptors
in splice site repression. Mol. Cell. Biol., 25, 6912–6920.
31. Reuter,J.S. and Mathews,D.H. (2010) RNAstructure: software for
RNA secondary structure prediction and analysis. BMC
Bioinformatics, 11, 129.
32. Kralovicova,J., Christensen,M.B. and Vorechovsky,I. (2005)
Biased exon/intron distribution of cryptic and de novo 30 splice
sites. Nucleic Acids Res., 33, 4882–4898.
33. Buratti,E., Chivers,M.C., Hwang,G. and Vorechovsky,I. (2011)
DBASS3 and DBASS5: databases of aberrant 30 and 50 splice
sites in human disease genes. Nucleic Acids Res., 39, D86–D91.
34. Jones,C.T., McIntosh,I., Keston,M., Ferguson,A. and Brock,D.J.
(1992) Three novel mutations in the cystic ﬁbrosis gene detected
by chemical cleavage: analysis of variant splicing and a nonsense
mutation. Hum. Mol. Genet., 1, 11–17.
35. Sakamoto,O., Ohura,T., Katsushima,Y., Fujiwara,I., Ogawa,E.,
Miyabayashi,S. and Iinuma,K. (2001) A novel intronic
mutation of the TAZ (G4.5) gene in a patient with Barth
syndrome: creation of a 50 splice donor site with variant GC
consensus and elongation of the upstream exon. Hum. Genet.,
109, 559–563.
36. Pagani,F., Buratti,E., Stuani,C., Bendix,R., Dork,T. and
Baralle,F.E. (2002) A new type of mutation causes a splicing
defect in ATM. Nat. Genet., 30, 426–429.
37. Pros,E., Gomez,C., Martin,T., Fabregas,P., Serra,E. and
Lazaro,C. (2008) Nature and mRNA effect of 282 different NF1
point mutations: focus on splicing alterations. Hum. Mutat., 29,
E173–E193.
38. Kossack,N., Simoni,M., Richter-Unruh,A., Themmen,A.P. and
Gromoll,J. (2008) Mutations in a novel, cryptic exon of the
luteinizing hormone/chorionic gonadotropin receptor gene cause
male pseudohermaphroditism. PLoS Med., 5, e88.
39. Yeo,G. and Burge,C.B. (2004) Maximum entropy modeling of
short sequence motifs with applications to RNA splicing signals.
J. Comput. Biol., 11, 377–394.
40. Yeakley,J.M., Morﬁn,J.P., Rosenfeld,M.G. and Fu,X.D. (1996)
A complex of nuclear proteins mediates SR protein binding to a
purine-rich splicing enhancer. Proc. Natl Acad. Sci. USA, 93,
7582–7587.
41. Coulter,L.R., Landree,M.A. and Cooper,T.A. (1997) Identiﬁcation
of a new class of exonic splicing enhancers by in vivo selection.
Mol. Cell. Biol., 17, 2143–2150.
42. Vorechovsky,I. (2010) Transposable elements in disease-associated
cryptic exons. Hum. Genet., 127, 135–154.
43. Hiller,M., Zhang,Z., Backofen,R. and Stamm,S. (2007)
Pre-mRNA secondary structures inﬂuence exon recognition.
PLoS Genet., 3, e204.
44. Zhang,X.H. and Chasin,L.A. (2004) Computational deﬁnition of
sequence motifs governing constitutive exon splicing. Genes Dev.,
18, 1241–1250.
45. Zhang,C., Li,W.H., Krainer,A.R. and Zhang,M.Q. (2008) RNA
landscape of evolution for optimal exon and intron
discrimination. Proc. Natl Acad. Sci. USA, 105, 5797–5802.
46. Wang,Z., Rolish,M.E., Yeo,G., Tung,V., Mawson,M. and
Burge,C.B. (2004) Systematic identiﬁcation and analysis of
exonic splicing silencers. Cell, 119, 831–845.
47. Krainer,A.R., Conway,G.C. and Kozak,D. (1990) The essential
pre-mRNA splicing factor SF2 inﬂuences 50 splice site selection
by activating proximal sites. Cell, 62, 35–42.
48. Eperon,I.C., Ireland,D.C., Smith,R.A., Mayeda,A. and
Krainer,A.R. (1993) Pathways for selection of 50 splice sites by
U1 snRNPs and SF2/ASF. EMBO J., 12, 3607–3617.
49. Gutell,R.R., Cannone,J.J., Shang,Z., Du,Y. and Serra,M.J. (2000)
A story: unpaired adenosine bases in ribosomal RNAs. J. Mol.
Biol., 304, 335–354.
50. Nissen,P., Ippolito,J.A., Ban,N., Moore,P.B. and Steitz,T.A.
(2001) RNA tertiary interactions in the large ribosomal
subunit: the A-minor motif. Proc. Natl Acad. Sci. USA, 98,
4899–4903.
Nucleic Acids Research, 2011,Vol.39, No. 16 708951. Schwartz,S., Gal-Mark,N., Kﬁr,N., Oren,R., Kim,E. and Ast,G.
(2009) Alu exonization events reveal features required for precise
recognition of exons by the splicing machinery. PLoS Comput.
Biol., 5, e1000300.
52. Lev-Maor,G., Ram,O., Kim,E., Sela,N., Goren,A., Levanon,E.Y.
and Ast,G. (2008) Intronic Alus inﬂuence alternative splicing.
PLoS Genet., 4, e1000204.
53. Sorek,R., Lev-Maor,G., Reznik,M., Dagan,T., Belinky,F.,
Graur,D. and Ast,G. (2004) Minimal conditions for exonization
of intronic sequences: 50 splice site formation in Alu exons.
Mol. Cell, 14, 221–231.
54. Lev-Maor,G., Sorek,R., Shomron,N. and Ast,G. (2003) The
birth of an alternatively spliced exon: 30 splice-site selection
in Alu exons. Science, 300, 1288–1291.
55. Ast,G. (2004) How did alternative splicing evolve?
Nat Rev. Genet., 5, 773–782.
56. Iwata,H. and Gotoh,O. (2011) Comparative analysis of
information contents relevant to recognition of introns in many
species. BMC Genomics, 12, 45.
57. Palaniswamy,R., Teglund,S., Lauth,M., Zaphiropoulos,P.G. and
Shimokawa,T. (2010) Genetic variations regulate alternative
splicing in the 50 untranslated regions of the mouse
glioma-associated oncogene 1, Gli1. BMC Mol Biol., 11, 32.
58. Tsai,K.W., Tseng,H.C. and Lin,W.C. (2008) Two wobble-splicing
events affect ING4 protein subnuclear localization and
degradation. Exp. Cell Res., 314, 3130–3141.
59. Flomen,R., Knight,J., Sham,P., Kerwin,R. and Makoff,A. (2004)
Evidence that RNA editing modulates splice site selection in the
5-HT2C receptor gene. Nucleic Acids Res., 32, 2113–2122.
60. Rueter,S.M., Dawson,T.R. and Emeson,R.B. (1999) Regulation of
alternative splicing by RNA editing. Nature, 399, 75–80.
61. Lev-Maor,G., Sorek,R., Levanon,E.Y., Paz,N., Eisenberg,E. and
Ast,G. (2007) RNA-editing-mediated exon evolution. Genome
Biol., 8, R29.
62. Kiran,A. and Baranov,P.V. (2010) DARNED: a DAtabase of
RNa EDiting in humans. Bioinformatics, 26, 1772–1776.
63. Fisher,C.W., Fisher,C.R., Chuang,J.L., Lau,K.S., Chuang,D.T.
and Cox,R.P. (1993) Occurrence of a 2-bp (AT) deletion allele
and a nonsense (G-to-T) mutant allele at the E2 (DBT) locus of
six patients with maple syrup urine disease: multiple-exon
skipping as a secondary effect of the mutations. Am. J. Hum.
Genet., 52, 414–424.
64. Schwarze,U., Starman,B.J. and Byers,P.H. (1999) Redeﬁnition of
exon 7 in the COL1A1 gene of type I collagen by an intron 8
splice-donor-site mutation in a form of osteogenesis imperfecta:
inﬂuence of intron splice order on outcome of splice-site
mutation. Am. J. Hum. Genet., 65, 336–344.
65. Hicks,M.J., Mueller,W.F., Shepard,P.J. and Hertel,K.J. (2010)
Competing upstream 50 splice sites enhance the rate of proximal
splicing. Mol. Cell. Biol., 30, 1878–1886.
66. Nemeroff,M.E., Utans,U., Kramer,A. and Krug,R.M. (1992)
Identiﬁcation of cis-acting intron and exon regions in inﬂuenza
virus NS1 mRNA that inhibit splicing and cause the formation of
aberrantly sedimenting presplicing complexes. Mol. Cell. Biol., 12,
962–970.
67. Alvarez,C.J. and Wise,J.A. (2001) Activation of a cryptic 50 splice
site by U1 snRNA. RNA, 7, 342–350.
68. Feldhahn,N., Rio,P., Soh,B.N., Liedtke,S., Sprangers,M.,
Klein,F., Wernet,P., Jumaa,H., Hofmann,W.K., Hanenberg,H.
et al. (2005) Deﬁciency of Bruton0s tyrosine kinase in B cell
precursor leukemia cells. Proc. Natl Acad. Sci. USA, 102,
13266–13271.
69. Raponi,M., Kralovicova,J., Copson,E., Divina,P., Eccles,D.,
Johnson,P.M., Baralle,D. and Vorechovsky,I. (2011) Prediction
of single-nucleotide substitutions that result in exon skipping:
identiﬁcation of a splicing silencer in BRCA1 exon 5.
Hum. Mutat., 32, 436–444.
70. Churbanov,A., Vorechovsky,I. and Hicks,C. (2010) A method of
predicting changes in human gene splicing induced by genetic
variants in context of cis-acting elements. BMC Bioinformatics,
11, 22.
71. Ramchatesingh,J., Zahler,A.M., Neugebauer,K.M., Roth,M.B.
and Cooper,T.A. (1995) A subset of SR proteins activates splicing
of the cardiac troponin T alternative exon by direct interactions
with an exonic enhancer. Mol. Cell. Biol., 15, 4898–4907.
72. Lynch,K.W. and Maniatis,T. (1996) Assembly of speciﬁc SR
protein complexes on distinct regulatory elements of the
Drosophila doublesex splicing enhancer. Genes Dev., 10,
2089–2101.
73. Tacke,R., Tohyama,M., Ogawa,S. and Manley,J.L. (1998) Human
Tra2 proteins are sequence-speciﬁc activators of pre-mRNA
splicing. Cell, 93, 139–148.
74. Nasim,M.T., Chernova,T.K., Chowdhury,H.M., Yue,B.G. and
Eperon,I.C. (2003) HnRNP G and Tra2beta: opposite effects on
splicing matched by antagonism in RNA binding. Hum. Mol.
Genet., 12, 1337–1348.
75. Hofmann,Y., Lorson,C.L., Stamm,S., Androphy,E.J. and Wirth,B.
(2000) Htra2-beta 1 stimulates an exonic splicing enhancer and
can restore full-length SMN expression to survival motor neuron
2 (SMN2). Proc. Natl Acad. Sci. USA, 97, 9618–9623.
76. Tsuda,K., Someya,T., Kuwasako,K., Takahashi,M., He,F.,
Unzai,S., Inoue,M., Harada,T., Watanabe,S., Terada,T. et al.
(2010) Structural basis for the dual RNA-recognition modes of
human Tra2-{beta} RRM. Nucleic Acids Res., 39, 1538–1553.
77. Clery,A., Jayne,S., Benderska,N., Dominguez,C., Stamm,S. and
Allain,F.H. (2011) Molecular basis of purine-rich RNA
recognition by the human SR-like protein Tra2-beta1.
Nat. Struct. Mol. Biol., 18, 443–450.
78. Giot,L., Bader,J.S., Brouwer,C., Chaudhuri,A., Kuang,B., Li,Y.,
Hao,Y.L., Ooi,C.E., Godwin,B., Vitols,E. et al. (2003) A protein
interaction map of Drosophila melanogaster. Science, 302,
1727–1736.
79. Doherty,E.A., Batey,R.T., Masquida,B. and Doudna,J.A. (2001)
A universal mode of helix packing in RNA. Nat. Struct. Biol.,
8, 339–343.
80. McCullough,A.J. and Berget,S.M. (1997) G triplets located
throughout a class of small vertebrate introns enforce intron
borders and regulate splice site selection. Mol. Cell. Biol., 17,
4562–4571.
81. Kanopka,A., Muhlemann,O. and Akusjarvi,G. (1996) Inhibition
by SR proteins of splicing of a regulated adenovirus pre-mRNA.
Nature, 381, 535–538.
82. Stoilov,P., Daoud,R., Nayler,O. and Stamm,S. (2004) Human
tra2-beta1 autoregulates its protein concentration by inﬂuencing
alternative splicing of its pre-mRNA. Hum. Mol. Genet., 13,
509–524.
83. Buratti,E., Stuani,C., De Prato,G. and Baralle,F.E. (2007) SR
protein-mediated inhibition of CFTR exon 9 inclusion:
molecular characterization of the intronic splicing silencer.
Nucleic Acids Res., 35, 4359–4368.
84. Makalowski,W., Mitchell,G.A. and Labuda,D. (1994) Alu
sequences in the coding regions of mRNA: a source of protein
variability. Trends Genet., 10, 188–193.
85. Lei,H., Day,I.N.M. and Vorechovsky,I. (2005) Exonization of
AluYa5 in the human ACE gene requires mutations in both 30
and 50 splice sites and is facilitated by a conserved splicing
enhancer. Nucleic Acids Res., 33, 3897–3906.
86. Vorechovsky,I. (2006) Aberrant 30 splice sites in human disease
genes: mutation pattern, nucleotide structure and comparison of
computational tools that predict their utilization. Nucleic Acids
Res., 34, 4630–4641.
87. Fairbrother,W.G., Yeh,R.F., Sharp,P.A. and Burge,C.B. (2002)
Predictive identiﬁcation of exonic splicing enhancers in human
genes. Science, 297, 1007–1013.
88. Fairbrother,W.G., Yeo,G.W., Yeh,R., Goldstein,P., Mawson,M.,
Sharp,P.A. and Burge,C.B. (2004) RESCUE-ESE identiﬁes
candidate exonic splicing enhancers in vertebrate exons.
Nucleic Acids Res., 32, W187–W190.
89. Cartegni,L., Wang,J., Zhu,Z., Zhang,M.Q. and Krainer,A.R.
(2003) ESEﬁnder: a web resource to identify exonic splicing
enhancers. Nucleic Acids Res., 31, 3568–3571.
90. Smith,P.J., Zhang,C., Wang,J., Chew,S.L., Zhang,M.Q. and
Krainer,A.R. (2006) An increased speciﬁcity score matrix for
the prediction of SF2/ASF-speciﬁc exonic splicing enhancers.
Hum. Mol. Genet., 15, 2490–2508.
91. Wollerton,M.C., Gooding,C., Wagner,E.J., Garcia-Blanco,M.A.
and Smith,C.W. (2004) Autoregulation of polypyrimidine tract
7090 Nucleic Acids Research, 2011,Vol.39, No. 16binding protein by alternative splicing leading to
nonsense-mediated decay. Mol. Cell, 13, 91–100.
92. Spellman,R., Llorian,M. and Smith,C.W. (2007) Crossregulation
and functional redundancy between the splicing regulator PTB
and its paralogs nPTB and ROD1. Mol. Cell, 27, 420–434.
93. Lander,E.S., Linton,L.M., Birren,B., Nusbaum,C., Zody,M.C.,
Baldwin,J., Devon,K., Dewar,K., Doyle,M., FitzHugh,W. et al.
(2001) Initial sequencing and analysis of the human genome.
Nature, 409, 860–921.
94. Steijlen,P.M., van Steensel,M.A., Jansen,B.J., Blokx,W., van de
Kerkhof,P.C., Happle,R. and van Geel,M. (2004) Cryptic
splicing at a non-consensus splice-donor in a patient with a
novel mutation in the plakophilin-1 gene. J. Invest. Dermatol.,
122, 1321–1324.
95. Spena,S., Duga,S., Asselta,R., Malcovati,M., Peyvandi,F. and
Tenchini,M.L. (2002) Congenital aﬁbrinogenemia: ﬁrst
identiﬁcation of splicing mutations in the ﬁbrinogen Bbeta-chain
gene causing activation of cryptic splice sites. Blood, 100,
4478–4484.
96. Harland,M., Taylor,C.F., Chambers,P.A., Kukalizch,K.,
Randerson-Moor,J.A., Gruis,N.A., de Snoo,F.A., ter
Huurne,J.A., Goldstein,A.M., Tucker,M.A. et al. (2005)
A mutation hotspot at the p14ARF splice site. Oncogene, 24,
4604–4608.
97. Tanioka,M., Budiyant,A., Ueda,T., Nagano,T., Ichihashi,M.,
Miyachi,Y. and Nishigori,C. (2005) A novel XPA gene mutation
and its functional analysis in a Japanese patient with xeroderma
pigmentosum group A. J. Invest. Dermatol., 125, 244–246.
98. Urban,Z., Michels,V.V., Thibodeau,S.N., Donis-Keller,H.,
Csiszar,K. and Boyd,C.D. (1999) Supravalvular aortic stenosis: a
splice site mutation within the elastin gene results in reduced
expression of two aberrantly spliced transcripts. Hum. Genet.,
104, 135–142.
99. Goyette,P., Frosst,P., Rosenblatt,D.S. and Rozen,R. (1995)
Seven novel mutations in the methylenetetrahydrofolate
reductase gene and genotype/phenotype correlations in
severe methylenetetrahydrofolate reductase deﬁciency.
Am. J. Hum. Genet., 56, 1052–1059.
100. Wimmer,K., Roca,X., Beiglbock,H., Callens,T., Etzler,J.,
Rao,A.R., Krainer,A.R., Fonatsch,C. and Messiaen,L. (2007)
Extensive in silico analysis of NF1 splicing defects uncovers
determinants for splicing outcome upon 50 splice-site disruption.
Hum. Mutat., 28, 599–612.
101. Hong,K., Guerchicoff,A., Pollevick,G.D., Oliva,A., Dumaine,R.,
de Zutter,M., Burashnikov,E., Wu,Y.S., Brugada,J., Brugada,P.
et al. (2005) Cryptic 50 splice site activation in SCN5A
associated with Brugada syndrome. J. Mol. Cell. Cardiol., 38,
555–560.
102. Ars,E., Serra,E., Garcia,J., Kruyer,H., Gaona,A., Lazaro,C. and
Estivill,X. (2000) Mutations affecting mRNA splicing are the
most common molecular defects in patients with
neuroﬁbromatosis type 1. Hum. Mol. Genet., 9, 237–247.
103. Roca,X., Sachidanandam,R. and Krainer,A.R. (2005)
Determinants of the inherent strength of human 50 splice sites.
RNA, 11, 683–698.
104. Divina,P., Kvitkovicova,A. and Vorechovsky,I. (2009) Ab initio
prediction of cryptic splice-site activation and exon skipping.
Eur. J. Hum. Genet., 17, 759–765.
Nucleic Acids Research, 2011,Vol.39, No. 16 7091